| Literature DB >> 24389286 |
Elaine S Pires Araujo1, Ruth Khalili Friedman2, Luis Antonio Bastos Camacho3, Monica Derrico2, Ronaldo Ismério Moreira2, Guilherme Amaral Calvet2, Marília Santini de Oliveira2, Valdilea Gonçalves Veloso2, José Henrique Pilotto4, Beatriz Grinsztejn2.
Abstract
OBJECTIVES: To describe the access to the interventions for the prevention of Human Immunodeficiency Virus (HIV) mother to child transmission and mother to child transmission rates in the outskirts of Rio de Janeiro, from 1999 to 2009.Entities:
Keywords: Antiretroviral chemoprophylaxis; Brazil; Cohort studies; HIV; HIV vertical transmission
Mesh:
Substances:
Year: 2014 PMID: 24389286 PMCID: PMC9427458 DOI: 10.1016/j.bjid.2013.11.002
Source DB: PubMed Journal: Braz J Infect Dis ISSN: 1413-8670 Impact factor: 3.257
Fig. 1Study flowchart.
Sociodemographic, clinical and obstetric characteristics of women and pregnancies included in the study, 1999–2009.
| Variables | % | |
|---|---|---|
| | ||
| <18 | 43 | 4.3 |
| 18–24 | 346 | 34.7 |
| 25–35 | 515 | 51.7 |
| >35 | 93 | 9.3 |
| | ||
| White | 270 | 27.1 |
| Non white | 727 | 72.9 |
| | ||
| <8 | 619 | 62.1 |
| ≥8 | 352 | 35.3 |
| Data not available | 26 | 2.6 |
| | ||
| No sexual partner | 24 | 2.4 |
| Positive | 282 | 28.3 |
| Negative | 187 | 18.8 |
| Unknown | 429 | 43.0 |
| Data not available | 75 | 7.5 |
| | ||
| None | 178 | 17.9 |
| 1 | 174 | 17.5 |
| 2 | 212 | 21.3 |
| ≥3 | 369 | 37.0 |
| Data not available | 64 | 6.4 |
| | ||
| Before pregnancy | 199 | 20.0 |
| During pregnancy | 449 | 45.0 |
| Intrapartum | 177 | 17.8 |
| Postpartum | 171 | 17.2 |
| Data not available | 1 | 0.1 |
| | ||
| Yes | 312 | 31.3 |
| No | 657 | 65.9 |
| Data not available | 28 | 2.8 |
| | ||
| <200 | 75 | 7.5 |
| 200–350 | 191 | 19.2 |
| >350 | 511 | 51.3 |
| Data not available | 220 | 22.0 |
| | ||
| No prenatal visits | 127 | 10.0 |
| <14 | 227 | 17.9 |
| 14–28 | 507 | 40.0 |
| >28 | 138 | 10.9 |
| Data not available | 270 | 21.3 |
| | ||
| None | 127 | 10.0 |
| 1–3 | 241 | 19.0 |
| 4–6 | 526 | 41.4 |
| ≥7 | 311 | 24.5 |
| Unknown | 64 | 5.0 |
| | ||
| HGNI | 960 | 75.7 |
| Other institution | 275 | 21.7 |
| Delivery outside the maternity | 22 | 1.7 |
| Data not available | 12 | 0.9 |
| | ||
| Elective cesarean | 531 | 41.8 |
| Vaginal | 514 | 40.5 |
| Emergency cesarean | 203 | 16.0 |
| Data not available | 21 | 1.7 |
| | ||
| No rupture | 865 | 68.2 |
| Rupture less than 3 h | 88 | 6.9 |
| Rupture between 3–6 h | 81 | 6.4 |
| Rupture more than 6 h | 97 | 7.6 |
| Rupture not knowing time | 81 | 6.4 |
| Data not available | 57 | 4.5 |
| | ||
| <37 | 185 | 14.6 |
| ≥37 | 1010 | 79.6 |
| Data not available | 74 | 5.8 |
Total number of women included in the cohort (n = 997); Total number of pregnancies that resulted in delivery in the cohort (n = 1269).
Time of HIV testing: the information is related to the first pregnancy in the cohort, e.g., the pregnancy at enrolment in the cohort.
Fig. 2Distribution of all women (A) and women who did not receive prenatal care (B) according to the municipality of origin.
PMTCT interventions delivered to pregnant women and their newborns, 1999–2009 (n = 1259).
| Interventions received by newborns, | Timing of HIV testing | Total | Subsequent pregnancies | |||
|---|---|---|---|---|---|---|
| Before pregnancy | During pregnancy | Labor | Postpartum | ( | ( | |
| ( | ( | ( | ( | |||
| ARV prophylaxis | 339 (70.3) | 324 (74.5) | – | – | 663 (52.7) | 196 (67.8) |
| ARV prophylaxis | 8 (1.7) | 5 (1.1) | – | – | 13 (1.0) | 4 (1.4) |
| ARV prophylaxis | 44 (9.1) | 21 (4.8) | – | – | 65 (5.2) | 33 (11.4) |
| ARV prophylaxis | 2 (0.4) | 3 (0.7) | – | 5 (0.4) | 1 (0.3) | |
| (IV) ZDV | 41 (8.5) | 63 (14.5) | 125 (72.7) | 229 (18.2) | 23 (8.0) | |
| (IV) ZDV | – | 1 (0.2) | – | – | 1 (0.1) | – |
| (IV) ZDV | 1 (0.2) | 2 (0.5) | 5 (2.9) | 8 (0.6) | – | |
| Formula | 14 (2.9) | 1 (0.2) | 23 (13.4) | 116 (68.2) | 154 (12.2) | 8 (2.8) |
| Only formula | 1 (0.2) | – | – | – | 1 (0.1) | 1 (0.3) |
| Only ARV syrup | 2 (0.4) | 1 (0.2) | 9 (5.2) | 49 (28.8) | 61 (4.8) | 1 (0.3) |
| None of the interventions | 1 (0.2) | – | – | 2 (1.2) | 3 (0.2) | 1 (0.3) |
ARV prophylaxis – ARV use during pregnancy.
(IV) ZDV – intravenous zidovudine.
Formula – newborns who were not breastfed and received infant formula.
ARV syrup – ARV syrup administered to newborns.
Among 482 newborns who were born to women diagnosed with HIV before pregnancy, 289 were born from subsequent pregnancies during the study period.
Of the 1260 newborns, data on timing of HIV testing of the women were available for 1259. Of the 1260 newborns, 53 had missing data in at least one intervention and they do not appear in the table, as we could not define which set of interventions they received.
Of the 482 newborns who were born to women diagnosed with HIV before pregnancy, 29 had missing data in at least one intervention and we could not define which set of interventions they received. Among these 29, at least 8 received (IV) ZDV, 14 received formula and at least 17 received ARV syrup.
Of the 435 newborns who were born to women diagnosed with HIV during pregnancy, 14 had missing data in at least one intervention and we could not define which set of interventions they received. Among these 14, all of them received ARV prophylaxis, 8 received (IV) ZDV, 11 received formula and 6 received ARV syrup.
Of the 172 newborns who were born to women diagnosed with HIV during delivery, 10 had missing data in at least one intervention and we could not define which set of interventions they received. Among these 10, at least 4 received (IV) ZDV, 5 received formula and 6 received ARV syrup.
Of the 170 newborns who were born to women diagnosed with HIV during the postpartum period, 3 had missing data in at least one intervention and we could not define which set of interventions they received. Among these 3, 2 received formula and all 3 received ARV syrup.
Of the 289 newborns from subsequent pregnancies in the cohort, 21 had missing data in at least one intervention and we could not define which set of interventions they received.
One newborn died and did not receive ARV syrup. The death was related to prematurity and hepatomegaly.
Fig. 3Estimated overall and annual MTCT rates, 1999–2009.